Business Context and Reporting Period
Company: Personalis, Inc. (PSNL)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Personalis develops and sells advanced cancer genomic testing services, including tumor-informed liquid biopsy tests for minimal residual disease (MRD) detection (NeXT Personal Dx) and comprehensive tumor profiling (NeXT Dx). The company serves pharmaceutical companies for clinical trials, diagnostic companies, and directly serves cancer patients through clinical diagnostics. Operations are consolidated into a single segment based in Fremont, California.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $69.6 million | $84.6 million |
| Net Loss | $(81.3) million | $(81.3) million |
| Loss Per Share (Basic & Diluted) | $(0.91) | $(1.37) |
| Cash, Cash Equivalents, and Short-Term Investments | $240.0 million | $185.0 million |
| Working Capital | $228.3 million | $171.9 million |
| Total Debt | $2.1 million | $1.8 million |
| Accumulated Deficit | $(631.3) million | $(550.0) million |
Note: Gross margin for 2025 was approximately 22.7% ($15.8 million gross profit / $69.6 million revenue), down from 31.9% in 2024, primarily due to lower fixed overhead absorption and increased clinical diagnostic test costs.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 18% year-over-year. This was driven primarily by an 77% drop in "Enterprise sales" ($5.9 million in 2025 vs. $25.4 million in 2024) following the expiration of minimum volume commitments with Natera, Inc.
- Population Sequencing Growth: Revenue from the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) increased 58% to $11.8 million, partially offsetting the decline in enterprise sales.
- Clinical Diagnostic Expansion: Clinical diagnostic revenue grew 166% to $2.0 million, with test volume increasing nearly 400% to 16,233 tests. This growth was supported by new Medicare coverage approvals.
- Operating Expenses: Total costs and expenses increased 3% to $157.7 million. Selling, General, and Administrative (SG&A) expenses rose 16% due to increased marketing and commercialization efforts for NeXT Personal Dx.
- One-Time Items: The 2024 results included an $18.3 million non-cash loss related to the remeasurement of Tempus warrants, which was not present in 2025.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Medicare Coverage Catalysts: The company secured Medicare coverage for NeXT Personal Dx for Stage II/III breast cancer (effective Oct 2025) and Stage I-III non-small cell lung cancer (effective Jan 2026). Management views these as key catalysts for clinical revenue growth.
- Strategic Partnerships: Expanded collaboration with Tempus AI to market NeXT Personal Dx for colorectal cancer and extended the agreement term through 2029. Tempus can now bundle Personalis testing with its own offerings for biopharma customers.
- Liquidity: The company ended 2025 with approximately $240 million in cash and short-term investments, bolstered by $109 million in net proceeds from its At-The-Market (ATM) sales program. Management believes this is sufficient to fund operations for at least the next 12 months.
- Profitability: The company expects to incur significant losses for the foreseeable future as it scales infrastructure and invests in commercialization.
Risks and Contingencies
- Customer Concentration: Revenue remains highly concentrated. Moderna (22%) and VA MVP (17%) accounted for 39% of 2025 revenue. The top five customers accounted for 62% of total revenue.
- Regulatory Uncertainty: While the FDA rescinded a 2024 rule on Laboratory Developed Tests (LDTs) in September 2025, the regulatory landscape remains complex. Future changes could require costly pre-market approvals.
- Supplier Dependency: The company relies on Illumina as the sole supplier for sequencers and associated reagents.
- Cybersecurity: In December 2025, a threat actor accessed a small number of user accounts, potentially exposing some patient Protected Health Information (PHI). No financial systems were compromised.
Investor Verification Checklist
- Customer Diversification: Verify the sustainability of revenue from Moderna and VA MVP, and the timeline for replacing the lost Natera revenue with new enterprise or clinical customers.
- Reimbursement Rates: Confirm actual reimbursement rates received from Medicare and private payors for NeXT Personal Dx to ensure they cover the cost of testing, as margins in the clinical segment were negative in 2025.
- Tempus Partnership Performance: Monitor the volume of tests generated through the expanded Tempus partnership to assess its effectiveness as a commercialization vector.
- Cash Burn Rate: Track quarterly cash usage against the $240 million cash balance to validate the 12-month runway estimate.
- Regulatory Status: Monitor any new FDA guidance or enforcement actions regarding LDTs that could impact the business model.